Arterial hypertension is a global leading cause of cardiovascular, cerebrovascular, and renal disease, as well as mortality. Although pharmacotherapy is safe and effective in lowering blood pressure (BP) and cardiovascular disease risk, BP control remains poor, and the mortality rates associated with high BP have been steadily increasing. Device-based therapies have been investigated to overcome barriers to pharmacotherapy, including non-adherence and low rates of persistence to daily medications. Among these device-based therapies, catheter-based renal denervation (RDN) has been most extensively examined over the past 15 years. In this state-of-the-art article, we summarise the rationale for RDN, review the available evidence, provide recommendations for a safe procedure, and discuss the role of RDN in current guidelines and clinical practice.
Keyphrases
- clinical practice
- blood pressure
- arterial hypertension
- cardiovascular disease
- cardiovascular events
- smoking cessation
- risk factors
- type diabetes
- physical activity
- hypertensive patients
- heart rate
- coronary artery disease
- clinical trial
- minimally invasive
- adipose tissue
- metabolic syndrome
- high resolution
- ultrasound guided
- blood glucose
- atomic force microscopy
- insulin resistance